DR LYDIA LAMB
About
Dr Lydia Lamb is a Consultant Endocrinologist with an interest in type 2 diabetes, pituitary and thyroid disorders, PCOS, Obesity, and other endocrine disorders. Her approach to patient care is centred around the unique needs and circumstances of each individual. She works closely with each patient to develop a personalised treatment plan that takes into account their medical history, lifestyle, and goals.
Dr Lamb completed her medical degree at the University of Western Australia, Perth and worked as a junior medical officer at hospitals across Western Australia including rural and remote placements in the Kimberley working for the Aboriginal Medical Service. She commenced her Advanced Endocrine Training in Perth before relocating to Sydney where she completed her specialist training and was awarded Fellowship to the Royal Australasian College of Physicians in 2019. As well as general endocrinology and diabetes, Dr Lamb’s training has included experience with endocrine disorders and diabetes in pregnancy. Her final year of training as the Pituitary Fellow at St Vincent’s Hospital, Sydney was a clinical and research role focusing on the management of pituitary disease.
Dr Lamb is currently a PhD Candidate at the University of NSW and the Garvan Institute of Medical Research investigating novel treatment options for the management of aggressive pituitary tumours and pituitary carcinomas. Dr Lamb is a VMO at North Shore Private Hospital, has an honorary appointment at St Vincent's Hospital and is affiliated with St Vincent's hospital Department of Endocrinology. She is a Conjoint Associate Lecturer at the University of New South Wales.
Dr Lamb regularly attends Multidisciplinary team meetings at St Vincent's Hospital to discuss interesting and complex clinical cases and attends diabetes and endocrinology conferences to remain up to date with the latest in evidence based clinical practice. She has published in peer-reviewed journals and presented her research and challenging clinical cases at national diabetes and endocrine conferences.
Publications
De Sousa SMC, Lenders NF, Lamb L, Inder WJ, McCormack AI.
Pituitary tumours: molecular and genetic aspects. J Endocrinol. 2023 Mar 1:JOE-22-0291. doi: 10.1530/JOE-22-0291. Epub ahead of print. PMID: 36951812.
Lamb LS, Sim HW, McCormack AI.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol. 2020 Nov 18;11:576027
Lamb, L.S., Samaras, K.
The endocrinopathies of lithium: common and treatable. Endocrinology Today, 2020; 9(3) 29-32.
Lamb L.S, Sim HW, McCormack A.I.
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—Are We There Yet?. Cancers, 2020, 12, 308.
Burman P, Lamb L.S, McCormack A.I.
Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives. Reviews in Endocrine and Metabolic Disorders, 2020.
Lamb, L.S, McCormack, A.I.
The genetics of pituitary disease. The Global Pituitary Voice, Journal of World Alliance of Pituitary Organisations. Edition 11, Oct 2019.
Lamb L.S., Alfonso H, Norman P.E., Davis T.M.E., Forbes J, Müench G, Irrgang F, Almeida O.P., Golledge J, Hankey G.J., Flicker L., Yeap B.B.
Advanced glycation end products and esRAGE are associated with bone turnover and incidence of hip fracture in older men. Journal of Clinical Endocrinology and Metabolism. Volume 103, Issue 11, 1 November 2018, Pages 4224–4231.
Hand R, Manning L, Ritter J.C, Norman P, Lamb L.S, Makepeace A, Snkhesara D, Hamilton E, Ingram P.
Antimicrobial stewardship opportunities among inpatients with diabetic foot infections: microbiology results from a tertiary hospital multidisciplinary unit. Internal Medicine Journal. Volume 49, Issue 4, 7 April 2019, Pages 533-536.
Abstracts
Lamb LS, Prins A, Brown SJ, Walsh JP, Lim EM.
Mechanism of hypercalcaemia in patients with primary hyperparathyroidism: role of 1,25(OH)2D’. Proceedings of the Endocrine Society of Australia, 2018.
Lamb LS, Henley D, Zhang R, Boyder C, Perriam B, Lim EM.
Comparison of LCMSMS, HPLC and two automated immunoassay methods in a cohort of patients with clinically confirmed Cushing’s syndrome’. Proceedings of the Endocrine Society of Australia, 2018.
Lamb LS, Alfonso H, Norman PE, Davis TME, Forbes J, Müench G, Irrgang F, Almeida O.P., Golledge J, Hankey GJ, Flicker L., Yeap BB.
Circulating advanced glycation end products and their endogenous secretory receptor are associated with bone turnover markers and with incidence of hip fracture in older men. Proceedings of the Endocrine Society of Australia; 2017; Perth: Clinical Endocrinology, 2018. Abstract number 107.
Lamb LS, Fegan GP, Beilin J, Bell D, Hooper A.
Novel PPARG mutation causing severe hypertriglyceridaemia and insulin resistant diabetes. Proceedings of the Australian Diabetes Association, 2017. Abstract number 374.
Hand R, Ingram P, Lamb LS, Sankhesara D, Dilevska T, Ryan E, Makepeace A, Ritter C, Manning L, Hamilton EJ. Microbiology results reveal antimicrobial stewardship opportunities amongst a Multidisciplinary Diabetic Foot Unit (MDFU) inpatient cohort. Proceedings of the Australian Diabetes Association, 2017. Abstract number 225.
Anil J, Davis WA, Lamb LS, Sankhesara D, Dilevska T, Ryan E, Ting M, Makepeace A, Fegan GP, Ritter C, Manning L, Hamilton EJ.
No difference in Alkaline phosphatase or C-reactive protein levels in Diabetic Foot Infections with or without osteomyelitis. Proceedings of the Australian Diabetes Association, 2017. Abstract number 283.
Hamilton, EJ, Davis WA, Lamb LS, Sankhesara D, Dilevska T, Ryan E, Baba M, Hiew J, Makepeace A, Fegan PG, Ritter C, Manning L.
Observational study of admissions to the inpatient Multidisciplinary Diabetic Foot Unit at Fiona Stanley Hospital: Patient outcomes at 12 months. Proceedings of the Australian Diabetes Association, 2017. Abstract number 286.
Anil J, Davis WA, Lamb LS, Sankhesara D, Dilevska T, Ryan E, Ting M, Makepeace A, Fegan GP, Ritter C, Manning L, Hamilton EJ.
Observational study of admissions to the inpatient Multidisciplinary Diabetic Foot Unit at Fiona Stanley Hospital: glycaemic control and renal function at 12 months. Proceedings of the Australian Diabetes Association, 2017. Abstract number 287.
Lamb LS, Sankhesara D, Dilevska T, Ryan E, Makepeace A, Fegan GP, Ritter C, Norman P, Manning L, Hamilton EJ. Observational study of admissions to the inpatient Multidisciplinary Diabetic Foot Unit at Fiona Stanley Hospital: experiences from the first year of operation. Proceedings of the Australian Diabetes Association, 2016. Abstract number 326.
Presentations
Lamb, L.S. New and emerging treatments for pituitary tumours. Australian Pituitary Foundation Seminar, Sept 2019.
Lamb, L.S. Case presentations. Sydney Pituitary Collaborative Group Meetings. Feb, May, Aug, Nov 2019
Lamb, LS. Mechanism of hypercalcaemia in patients with primary hyperparathyroidism: role of 1,25(OH)2D. Endocrine Society of Australia Annual Scientific Meeting, Adelaide, August 2018
Lamb, LS. An unusual presentation of diabetes. Endocrine Society of Australia Annual Seminar Meeting, Canberra, May 2018.
Lamb LS. Circulating advanced glycation end products and their endogenous secretory receptor are associated with bone turnover markers and with incidence of hip fracture in older men.’ Manuscript has been submitted for publication. Bryan Hudson Clinical Awards Session, Endocrine Society of Australia Annual Scientific Meeting, Perth, 2017.
Lamb LS. Pituitary case 2: IgG4 hypophysitis. Endocrine Society of Australia Annual Seminar Meeting, Melbourne, May 2017.